GIT2

Across TCGA pan-cancer cohorts, GIT2 mass-spec protein differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of GIT2’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where GIT2 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types GIT2 is over-expressed in tumor, although a few such as COAD and LSCC show the opposite, repressed pattern.

CCRCC, COAD, and LSCC are the cancer types where GIT2 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in GIT2 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Male	III,IV	+0.692	<.001	12	view →
COAD	Male	III,IV	−0.231	<.001	10	view →
LSCC	Male	III,IV	−0.385	<.001	8	view →
LUAD	Male	II,III,IV	−0.146	<.001	8	view →
HNSC	Female	IV	+0.370	.001	5	view →
PDAC	All	IV	−0.417	.025	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

GIT2–CCRCC

Open the CCRCC breakdown →